United States · FDA National Drug Code directory
Darzalex IV
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 57894-505_a47a0bd7-3709-44e0-98ab-e2306b5887fe
- Product NDC
- 57894-505
- Form
- INJECTION, SOLUTION, CONCENTRATE
- Composition / generic term
- Daratumumab
- Labeler
- Janssen Biotech, Inc.
- Marketing category
- BLA
- Marketing start / end (source format)
- 20211015
- Source listing expiry
- 20271231
Source-listed ingredients
- DARATUMUMAB — 100 mg/5mL
These values do not establish equivalence or a dose recommendation.
Packages
- 1 VIAL, SINGLE-DOSE in 1 BOX (57894-505-05) / 5 mL in 1 VIAL, SINGLE-DOSE · 57894-505-05
- 1 VIAL, SINGLE-DOSE in 1 BOX (57894-505-20) / 20 mL in 1 VIAL, SINGLE-DOSE · 57894-505-20
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →